Physician profile
Alejandro O Roca
NPI 1629034343
$27,664.54
in general payments reported to CMS, 2019-2025
82 companies · $4,446 in 2025
The $4,446 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,172 · 2020: $3,191 · 2021: $4,575 · 2022: $4,126 · 2023: $3,701 · 2024: $4,454 · 2025: $4,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $91.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,509.84 |
| Education | $91.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,143.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $2,618.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $2,185.42 | 2019-2025 | Rinvoq, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,793.09 | 2019-2025 | Benlysta, Shingrix, Arexvy |
| Amgen INC. | $1,556.91 | 2019-2025 | Otezla, Evenity, Repatha |
| Lilly USA, LLC | $1,333.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Mallinckrodt Hospital Products INC. | $1,029.27 | 2021-2025 | Acthar |
| Pfizer INC. | $964.83 | 2019-2025 | |
| Astellas Pharma US INC | $929.53 | 2019-2024 | Veozah, Myrbetriq |
| Ucb, INC. | $908.14 | 2019-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $877.00 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Radius Health, INC. | $753.34 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $605.22 | 2019-2025 | |
| Esperion Therapeutics, INC. | $511.01 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $499.01 | 2019-2025 | Spravato, Xarelto |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Roca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.